Prognose

Køb
  1
Behold
  0
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Virbac exceeds first-half sales forecasts and confirms 2026 targets

    In the first half Virbac reported sales of €768m (+7.4% currency-adjusted) and quarterly sales of €384m, slightly above the LSEG consensus estimate of €381m. Growth was driven mainly by volume and product mix (about 5.4 percentage points); price adjustments contributed roughly 2 percentage points. The company confirmed its 2026 targets: sales growth of 5.5–7.5% and an adjusted operating margin of around 17%. » Mere på de.investing.com


  • Virbac confirms full-year guidance after 7.7% sales rise in first quarter

    Virbac reports currency- and portfolio-adjusted sales growth of 7.7% in Q1, driven by strong North America business (+20.7%) and gains in international markets (+9.1%). Volume increases contributed around 6 percentage points to growth, price adjustments about 2%; exchange rates weighed with roughly -5.5%. The Thyronorm acquisition added about 1%; pet products and livestock showed double-digit and strong increases, while regulatory delays weighed on other businesses. Virbac confirms its full-year guidance of +5.5–7.5% sales growth at constant exchange rates, expects an adjusted EBITA margin of around 17% and cash generation of about €80m with capex of around €125m. » Mere på de.investing.com


  • Virbac records 7.9% organic growth in 2025 despite currency headwinds

    Virbac reports 2025 revenue of €1,464.7m (+8.7% nominal, +7.9% organic) and adjusted EBIT of €234.4m with a margin of 16.0%. Currency losses weighed on revenue and EBIT, while R&D spending rose to a record level (€115.1m) and the pipeline includes around 40 prioritized projects. North America was the strongest growth region at +14.7%; pets continue to account for the majority of sales (58.8%). The Thyronorm acquisition strengthens the endocrinology platform; management expects 2026 organic revenue growth of 5.5–7.5% and an adjusted EBIT margin of around 17%. » Mere på de.investing.com


  • Virbac reports 2025 revenue growth, operational pressures weigh on margins

    Virbac posted 2025 revenue of €1,464.7m (+7.9% currency- and portfolio-adjusted) and adjusted EBITA of €234.4m, corresponding to a margin of 16.3%, meeting guidance. Net profit rose 3.2% to €150.5m, while gross margin was hit by 0.7 percentage points due to a temporary halt in antigen production and higher inventory write-downs. R&D spending reached a record level, net debt stood at €172.8m, and a net dividend of €1.45 per share is planned for the annual general meeting. For 2026 Virbac confirms currency- and portfolio-adjusted revenue growth of 5.5–7.5% (including Thyronorm) and targets an adjusted EBITA margin of around 17%; US tariffs have already been factored in. » Mere på de.investing.com


  • Virbac soutenu par la recommandation positive d'Oddo BHF

    Virbac a enregistré une forte hausse en Bourse après qu'Oddo BHF a relevé sa recommandation de Neutre à Surperformance et augmenté son objectif de cours à 395 euros. Les analystes saluent la solidité des fondamentaux de Virbac et anticipent une amélioration de la marge opérationnelle d'ici 2030. Toutefois, le deuxième trimestre et le premier semestre 2025 seront affectés par une base de comparaison élevée, avec des perspectives plus favorables attendues à partir du troisième trimestre. » Mere på abcbourse.com

I 2026 har Virbac allerede udloddet 1,45 € i udbytte. Den seneste udlodning fandt sted i juli.

Virksomhedstal

I det seneste kvartal havde Virbac en omsætning på 761,99 mio. € og et nettoresultat på 86,69 mio. €

(EUR) juni 2026
YoY
Omsætning 761,99 mio. -
Bruttofortjeneste 278,39 mio. -
Nettoresultat 86,69 mio. -
EBITDA 165,66 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
2,93 mia. €
Antal aktier
8,38 mio.
Højeste/laveste i 52 uger
397,64 € - 315,33 €
Udbytteafkast
0,41 %
Udbytte TTM
1,45 €
Beta
0,78
P/E (PE Ratio)
18,42
PEG (PEG Ratio)
1,08
K/I (PB Ratio)
2,35
P/S (PS Ratio)
1,92

Virksomhedsprofil

Virbac SA fremstiller og sælger en række produkter og tjenester til selskabsdyr og fødevareproducerende dyr i Frankrig, Europa, Latinamerika, Nordamerika, Asien-Stillehavsregionen, Mellemøsten og Afrika. Selskabet tilbyder en række vacciner, tandhygiejne, reproduktion, dermatologi, parasitmidler, diagnostik, antibiotika og akvakulturprodukter samt veterinærmedicin til anæstesi, geriatri, adfærd og injicerbare mikronæringsstoffer, og desuden foder til dyr og elektronisk identifikation. Det betjener dyrlæger, landmænd og dyreejere. Virbac SA blev grundlagt i 1968 og har hovedkvarter i Carros, Frankrig.

Navn
Virbac
CEO
Paul Martingell
Hjemsted Carros, pa
Frankrig
Websted
Børsnotering
07.07.1992
Medarbejdere 6.442

Tickersymboler

Børs Symbol
Euronext
VIRP.PA
Pnk
VRBCF
Frankfurt
V16.F
Düsseldorf
V16.DU
London
0NM7.L
Paris
VIRP.PA
München
V16.MU
SIX
VIRP.SW
🍪

Parqet  bruger cookies. Læs mere